'Has to be a balance between innovation, affordability of drugs'

CNN-IBN | Apr 01, 2013 at 03:37pm

After the Supreme Court dismissed Swiss pharma company Novartis' plea for a patent on its cancer drug Glivec, pharma expert vikas Dandekar said, 'This will be a far reaching decision. Innovation on one side, access and affordability on the other side. The balance has to be done'.